{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:41:39Z","timestamp":1785436899792,"version":"3.56.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"44","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,11,18]]},"DOI":"10.1038\/s41388-025-03576-w","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:01:39Z","timestamp":1758589299000},"page":"4324-4337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1707-6621","authenticated-orcid":false,"given":"Haoyue","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-1396","authenticated-orcid":false,"given":"Guohai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2216-2724","authenticated-orcid":false,"given":"Yawen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5256-3900","authenticated-orcid":false,"given":"Dan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-6413","authenticated-orcid":false,"given":"Haojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-3780","authenticated-orcid":false,"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"3576_CR1","first-page":"A68","volume":"19","author":"K Tomczak","year":"2015","unstructured":"Tomczak K, Czerwi\u0144ska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol. 2015;19:A68\u201377.","journal-title":"Contemp Oncol"},{"key":"3576_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398:131\u201342.","journal-title":"Lancet"},{"key":"3576_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrm3330","volume":"13","author":"MS Song","year":"2012","unstructured":"Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13:283\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3576_CR4","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ajhg.2009.05.007","volume":"84","author":"JS Friedman","year":"2009","unstructured":"Friedman JS, Ray JW, Waseem N, Johnson K, Brooks MJ, Hugosson T, et al. Mutations in a BTB-Kelch protein, KLHL7, cause autosomal-dominant retinitis pigmentosa. Am J Hum Genet. 2009;84:792\u2013800.","journal-title":"Am J Hum Genet"},{"key":"3576_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1747-1028-8-3","volume":"8","author":"S L\u00fchrig","year":"2013","unstructured":"L\u00fchrig S, Kolb S, Mellies N, Nolte J. The novel BTB-kelch protein, KBTBD8, is located in the Golgi apparatus and translocates to the spindle apparatus during mitosis. Cell Div. 2013;8:3.","journal-title":"Cell Div"},{"key":"3576_CR6","first-page":"1194","volume":"28","author":"R Perez-Torrado","year":"2006","unstructured":"Perez-Torrado R, Yamada D, Defossez PA. Born to bind: the BTB protein-protein interaction domain. BioEssays N Rev Mol Cell Dev Biol. 2006;28:1194\u2013202.","journal-title":"BioEssays N Rev Mol Cell Dev Biol"},{"key":"3576_CR7","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1074\/jbc.M112.437996","volume":"288","author":"P Canning","year":"2013","unstructured":"Canning P, Cooper CDO, Krojer T, Murray JW, Pike ACW, Chaikuad A, et al. Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. J Biol Chem. 2013;288:7803\u201314.","journal-title":"J Biol Chem"},{"key":"3576_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-4-11","volume":"4","author":"VA Gupta","year":"2014","unstructured":"Gupta VA, Beggs AH. Kelch proteins: emerging roles in skeletal muscle development and diseases. Skelet Muscle. 2014;4:11.","journal-title":"Skelet Muscle"},{"key":"3576_CR9","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1126\/science.1175065","volume":"325","author":"WL Yang","year":"2009","unstructured":"Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009;325:1134\u20138.","journal-title":"Science"},{"key":"3576_CR10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1126\/science.1179972","volume":"325","author":"DF Restuccia","year":"2009","unstructured":"Restuccia DF, Hemmings BA. Cell signaling. Blocking Akt-ivity. Science. 2009;325:1083\u20134.","journal-title":"Science"},{"key":"3576_CR11","doi-asserted-by":"publisher","first-page":"12319","DOI":"10.1074\/jbc.M701019200","volume":"282","author":"S Jiang","year":"2007","unstructured":"Jiang S, Seng S, Avraham HK, Fu Y, Avraham S. Process elongation of oligodendrocytes is promoted by the Kelch-related protein MRP2\/KLHL1. J Biol Chem. 2007;282:12319\u201329.","journal-title":"J Biol Chem"},{"key":"3576_CR12","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NA Franken","year":"2006","unstructured":"Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315\u20139.","journal-title":"Nat Protoc"},{"key":"3576_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"3576_CR14","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal"},{"key":"3576_CR15","doi-asserted-by":"publisher","first-page":"e8478","DOI":"10.15252\/emmm.201708478","volume":"10","author":"Y Yan","year":"2018","unstructured":"Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, et al. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Mol Med. 2018;10:e8478.","journal-title":"EMBO Mol Med"},{"key":"3576_CR16","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.7150\/thno.34700","volume":"9","author":"L Ma","year":"2019","unstructured":"Ma L, Yan Y, Bai Y, Yang Y, Pan Y, Gang X, et al. Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer. Theranostics. 2019;9:5020\u201334.","journal-title":"Theranostics"},{"key":"3576_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molcel.2009.07.025","volume":"36","author":"DF Lee","year":"2009","unstructured":"Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell. 2009;36:131\u201340.","journal-title":"Mol Cell"},{"key":"3576_CR18","doi-asserted-by":"publisher","first-page":"29830","DOI":"10.1074\/jbc.M305349200","volume":"278","author":"AH Kim","year":"2003","unstructured":"Kim AH, Sasaki T, Chao MV. JNK-interacting protein 1 promotes Akt1 activation. J Biol Chem. 2003;278:29830\u20136.","journal-title":"J Biol Chem"},{"key":"3576_CR19","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1096\/fj.06-7684com","volume":"21","author":"M Noguchi","year":"2007","unstructured":"Noguchi M, Ropars V, Roumestand C, Suizu F. Proto-oncogene TCL1: more than just a coactivator for Akt. FASEB J. 2007;21:2273\u201384.","journal-title":"FASEB J"},{"key":"3576_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.onc.1201947","volume":"17","author":"A Bellacosa","year":"1998","unstructured":"Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene. 1998;17:313\u201325.","journal-title":"Oncogene"},{"key":"3576_CR21","first-page":"3613","volume":"18","author":"D Zhou","year":"2019","unstructured":"Zhou D, Sun Y, Jia Y, Liu D, Wang J, Chen X, et al. Bioinformatics and functional analyses of key genes in smoking-associated lung adenocarcinoma. Oncol Lett. 2019;18:3613\u201322.","journal-title":"Oncol Lett"},{"key":"3576_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26049-6","volume":"12","author":"J Ma","year":"2021","unstructured":"Ma J, Shi Q, Cui G, Sheng H, Botuyan MV, Zhou Y, et al. SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. Nat Commun. 2021;12:5779.","journal-title":"Nat Commun"},{"key":"3576_CR23","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1158\/1078-0432.CCR-22-2585","volume":"29","author":"D Pook","year":"2023","unstructured":"Pook D, Geynisman DM, Carles J, de Braud F, Joshua AM, P\u00e9rez-Gracia JL, et al. A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29:3292\u2013300.","journal-title":"Clin Cancer Res"},{"key":"3576_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00280-022-04488-2","volume":"90","author":"N Kotani","year":"2022","unstructured":"Kotani N, Wilkins JJ, Wade JR, Dang S, Sutaria DS, Yoshida K, et al. Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study. Cancer Chemother Pharm. 2022;90:511\u201321.","journal-title":"Cancer Chemother Pharm"},{"key":"3576_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41556-023-01092-1","volume":"25","author":"B Wu","year":"2023","unstructured":"Wu B, Liu DA, Guan L, Myint PK, Chin L, Dang H, et al. Stiff matrix induces exosome secretion to promote tumour growth. Nat Cell Biol. 2023;25:415\u201324.","journal-title":"Nat Cell Biol"},{"key":"3576_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s43018-022-00394-x","volume":"3","author":"KH Lin","year":"2022","unstructured":"Lin KH, Rutter JC, Xie A, Killarney ST, Vaganay C, Benaksas C, et al. P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. Nat Cancer. 2022;3:837\u201351.","journal-title":"Nat Cancer"},{"key":"3576_CR27","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/1878-0261.13577","volume":"18","author":"T Sugawara","year":"2024","unstructured":"Sugawara T, Nevedomskaya E, Heller S, B\u00f6hme A, Lesche R, von Ahsen O, et al. Dual targeting of the androgen receptor and PI3K\/AKT\/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Mol Oncol. 2024;18:726\u201342.","journal-title":"Mol Oncol"},{"key":"3576_CR28","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-12-3072","volume":"19","author":"J Lin","year":"2013","unstructured":"Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res. 2013;19:1760\u201372.","journal-title":"Clin Cancer Res"},{"key":"3576_CR29","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1158\/1078-0432.CCR-13-0978","volume":"19","author":"Y Yan","year":"2013","unstructured":"Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodr\u00edguez O, et al. Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clin Cancer Res. 2013;19:6976\u201386.","journal-title":"Clin Cancer Res"},{"key":"3576_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/978-3-030-32656-2_14","volume":"1210","author":"Y Yan","year":"2019","unstructured":"Yan Y, Huang H. Interplay among PI3K\/AKT, PTEN\/FOXO and AR signaling in prostate cancer. Adv Exp Med Biol. 2019;1210:319\u201331.","journal-title":"Adv Exp Med Biol"},{"key":"3576_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ng.370","volume":"41","author":"BS Carver","year":"2009","unstructured":"Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41:619\u201324.","journal-title":"Nat Genet"},{"key":"3576_CR32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ng.371","volume":"41","author":"JC King","year":"2009","unstructured":"King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41:524\u20136.","journal-title":"Nat Genet"},{"key":"3576_CR33","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1158\/1078-0432.CCR-17-2006","volume":"24","author":"Y Yang","year":"2018","unstructured":"Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, et al. PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer. Clin Cancer Res. 2018;24:834\u201346.","journal-title":"Clin Cancer Res"},{"key":"3576_CR34","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ccell.2017.02.004","volume":"31","author":"M Blattner","year":"2017","unstructured":"Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, et al. SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K\/mTOR and AR signaling. Cancer Cell. 2017;31:436\u201351.","journal-title":"Cancer Cell"},{"key":"3576_CR35","doi-asserted-by":"crossref","unstructured":"Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, et al. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Mol Med. 2018; 10: e8478.","DOI":"10.15252\/emmm.201708478"},{"key":"3576_CR36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nm.4379","volume":"23","author":"P Zhang","year":"2017","unstructured":"Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017;23:1055\u201362.","journal-title":"Nat Med"},{"key":"3576_CR37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/0008-5472.CAN-22-2801","volume":"83","author":"H Zhang","year":"2023","unstructured":"Zhang H, Jin X, Huang H. Deregulation of SPOP in Cancer. Cancer Res. 2023;83:489\u201399.","journal-title":"Cancer Res"},{"key":"3576_CR38","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/35085597","volume":"412","author":"C Wang","year":"2001","unstructured":"Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001;412:346\u201351.","journal-title":"Nature"},{"key":"3576_CR39","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1128\/MCB.02098-07","volume":"28","author":"DB Conze","year":"2008","unstructured":"Conze DB, Wu CJ, Thomas JA, Landstrom A, Ashwell JD. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activation. Mol Cell Biol. 2008;28:3538\u201347.","journal-title":"Mol Cell Biol"},{"key":"3576_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","volume":"5","author":"L Deng","year":"2020","unstructured":"Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5:11.","journal-title":"Signal Transduct Target Ther"},{"key":"3576_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ceca.2014.03.002","volume":"55","author":"PP Perissinotti","year":"2014","unstructured":"Perissinotti PP, Ethington EG, Cribbs L, Koob MD, Martin J, Piedras-Renter\u00eda ES. Down-regulation of endogenous KLHL1 decreases voltage-gated calcium current density. Cell Calcium. 2014;55:269\u201380.","journal-title":"Cell Calcium"},{"key":"3576_CR42","doi-asserted-by":"publisher","first-page":"e00508","DOI":"10.1128\/MCB.00508-16","volume":"37","author":"E Sasaki","year":"2017","unstructured":"Sasaki E, Susa K, Mori T, Isobe K, Araki Y, Inoue Y, et al. Knockout mice reveal the physiological role of KLHL3 and the pathophysiology of pseudohypoaldosteronism type II caused by mutant KLHL3. Mol Cell Biol. 2017;37:e00508\u2013516.","journal-title":"Mol Cell Biol"},{"key":"3576_CR43","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1073\/pnas.1421441112","volume":"112","author":"Y Gong","year":"2015","unstructured":"Gong Y, Wang J, Yang J, Gonzales E, Perez R, Hou J. KLHL3 regulates paracellular chloride transport in the kidney by ubiquitination of claudin-8. Proc Natl Acad Sci USA. 2015;112:4340\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3576_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0962-8924(99)01673-6","volume":"10","author":"J Adams","year":"2000","unstructured":"Adams J, Kelso R, Cooley L. The kelch repeat superfamily of proteins: propellers of cell function. Trends Cell Biol. 2000;10:17\u201324.","journal-title":"Trends Cell Biol"},{"key":"3576_CR45","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.tibs.2017.09.002","volume":"42","author":"YT Kwon","year":"2017","unstructured":"Kwon YT, Ciechanover A. The ubiquitin code in the ubiquitin-proteasome system and autophagy. Trends Biochem Sci. 2017;42:873\u201386.","journal-title":"Trends Biochem Sci"},{"key":"3576_CR46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425\u201379.","journal-title":"Annu Rev Biochem"},{"key":"3576_CR47","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.str.2016.01.007","volume":"24","author":"CA Casta\u00f1eda","year":"2016","unstructured":"Casta\u00f1eda CA, Dixon EK, Walker O, Chaturvedi A, Nakasone MA, Curtis JE, et al. Linkage via K27 bestows ubiquitin chains with unique properties among polyubiquitins. Structure. 2016;24:423\u201336.","journal-title":"Structure"},{"key":"3576_CR48","doi-asserted-by":"publisher","first-page":"7429","DOI":"10.1021\/jacs.6b04031","volume":"138","author":"M Pan","year":"2016","unstructured":"Pan M, Gao S, Zheng Y, Tan X, Lan H, Tan X, et al. Quasi-racemic X-ray structures of K27-linked ubiquitin chains prepared by total chemical synthesis. J Am Chem Soc. 2016;138:7429\u201335.","journal-title":"J Am Chem Soc"},{"key":"3576_CR49","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1002\/anie.201810814","volume":"58","author":"M Pan","year":"2019","unstructured":"Pan M, Zheng Q, Ding S, Zhang L, Qu Q, Wang T, et al. Chemical protein synthesis enabled mechanistic studies on the molecular recognition of K27-linked ubiquitin chains. Angew Chem Int Ed Engl. 2019;58:2627\u201331.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3576_CR50","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s13046-019-1317-6","volume":"38","author":"C Ciardiello","year":"2019","unstructured":"Ciardiello C, Leone A, Lanuti P, Roca MS, Moccia T, Minciacchi VR, et al. Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation. J Exp Clin Cancer Res. 2019;38:317.","journal-title":"J Exp Clin Cancer Res"},{"key":"3576_CR51","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.molcel.2020.07.028","volume":"79","author":"Z Hong","year":"2020","unstructured":"Hong Z, Zhang W, Ding D, Huang Z, Yan Y, Cao W, et al. DNA damage promotes TMPRSS2-ERG oncoprotein destruction and prostate cancer suppression via signaling converged by GSK3\u03b2 and WEE1. Mol Cell. 2020;79:1008\u201323.e1004.","journal-title":"Mol Cell"},{"key":"3576_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molcel.2018.10.034","volume":"73","author":"X Jin","year":"2019","unstructured":"Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, et al. Phosphorylated RB promotes cancer immunity by inhibiting NF-\u03baB activation and PD-L1 expression. Mol Cell. 2019;73:22\u201335.e26.","journal-title":"Mol Cell"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03576-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03576-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03576-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:02:23Z","timestamp":1761606143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03576-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":52,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2025,11,18]]}},"alternative-id":["3576"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03576-w","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Human tissue samples were obtained from the FDUSCC Biobank (ethics approval number: 050432-4-1212B) and followed protocols approved by the Ethics Committee of FDUSCC. Informed consent for sample collection and research use was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}